Compare Mutual Funds
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹500
-
Expense Ratio
2.95
-
NAV
₹10.77
-
Fund Started
06 Dec 2024
-
Fund Size
₹332.52 Cr
-
Exit Load
1% for redemption within 3 Months
-
1 Year
9.04%
-
3 Year
-
-
5 Year
-
-
Equity
96.71%
-
Cash
1.59%
-
Top 10 Holdings
Divi's Laboratories Ltd. | 9.10% |
Sun Pharmaceutical Industries Ltd. | 9.00% |
Aurobindo Pharma Ltd. | 6.57% |
Apollo Hospitals Enterprise Ltd. | 6.46% |
Piramal Pharma Ltd. | 6.27% |
Torrent Pharmaceuticals Ltd. | 5.13% |
Rubicon Research Ltd. | 4.48% |
Emcure Pharmaceuticals Ltd. | 4.26% |
Neuland Laboratories Ltd. | 3.96% |
Max Healthcare Institute Ltd. | 3.90% |
-
Name
-
-
Start Date
-
-
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
-
Launch Date
06 Dec 2024
-
